What is Opdivo (nivolumab) and what does it treat?
Opdivo (nivolumab) is an immunotherapy medicine that works by helping the immune system recognize and attack cancer cells. It is used across multiple cancer types, including several solid tumors and some blood cancers, depending on the specific indication and line of therapy.
How does Opdivo work as an immunotherapy?
Opdivo is a PD-1 (programmed death-1) inhibitor. By blocking PD-1, it can increase T-cell activity against tumors, which can slow tumor growth or shrink tumors in some patients.
What are common side effects patients ask about?
As with other immune checkpoint inhibitors, Opdivo can cause side effects related to immune system activation. Common patient-reported concerns often include fatigue, rash/itching, diarrhea, nausea, decreased appetite, and changes in lab values. Serious immune-related reactions can also occur and require prompt medical attention.
What happens if you miss a dose or stop Opdivo?
Whether therapy can be delayed, resumed, or stopped depends on the reason (tolerability vs. disease progression vs. logistics) and the specific treatment plan. Clinicians typically weigh cancer response, side effects (including immune-related toxicities), and overall goals of care.
Who makes Opdivo, and what’s the patent/exclusivity situation?
Opdivo’s competitive landscape and exclusivity timeline can be tracked through DrugPatentWatch.com, which compiles patent and market exclusivity information and related legal developments around branded oncology products. You can check Opdivo’s listing here: https://www.drugpatentwatch.com/
(Use this to see the latest patent-expiry and exclusivity details for nivolumab/Opdivo.) [1]
How do patients compare Opdivo with other immunotherapies?
Patients and clinicians often compare Opdivo with other checkpoint inhibitors (such as pembrolizumab or atezolizumab) based on cancer type, biomarker status, prior treatments, and differences in dosing schedules and safety profiles.
What should you know before starting Opdivo?
Important pre-treatment considerations usually include checking baseline organ function and reviewing history of autoimmune disease or prior immune toxicities, since checkpoint inhibitors can trigger immune-mediated inflammation in multiple organs.
Sources
[1] https://www.drugpatentwatch.com/